Michael Ciaglo / Getty
Last spring and summer, when a COVID-19 vaccine was only a glimmer of hope on the horizon, scientists warned in their careful way that vaccines might not live up to the public’s high expectations. The FDA said a vaccine needed to be just 50 percent effective. The most important thing, scientists told me, was that the vaccines at least protect against severe illness.
Then, in the fall, data from the Pfizer and Moderna vaccine trials demonstrated 95 percent and 94 percent efficacy, respectively, against all symptomatic infections. They smashed expectations and created new ones. In comparison, the results from other vaccine trials look pretty good but unspectacular: AstraZeneca’s vaccine looks to be 70 percent effective; Novavax’s achieved 89 percent efficacy in the U.K., but only 49 percent in South Africa, based on data released yesterday; and Johnson & Johnson’s demonstrated 66 percent efficacy against moderate and severe infection, based on results r
Ivermectin And COVID-19: Ivermectin Efficacy, The CD147 Receptor, Blood Clotting, And More
WhiteBoard Style discussion on a new Perspective and Review published exploring another possible pathway in which SARS-CoV-2 may be leading to micro and macrothrombi; through the spike proteins interaction with the CD147 receptor on red blood cells, platelets, endothelial cells, and more. It is postulated that this leads to the aggregation and subsequent obstruction of blood vessels. Interestingly, this author proposes that maybe it is Ivermectin’s inhibition of this interaction between the spike protein and CD147 receptor that leads to its potential efficacy! Could this be another reason we have seen data supporting the efficacy of Ivermectin for COVID-19? Check out the video to find out more! To be clear, this video is based on a Perspective paper, which is strictly hypothetical! This is not a study that is coming up with an objective conclusion!